Literature DB >> 23645771

Complete necrosis of a giant cell tumor with high expression of PPARγ: a case report.

Akihiko Takeuchi1, Norio Yamamoto, Hideji Nishida, Hiroaki Kimura, Hiroko Ikeda, Hiroyuki Tsuchiya.   

Abstract

Giant cell tumor of the bone (GCTB) is a common primary benign tumor, but in some cases, it behaves aggressively, resulting in tumor recurrence. The standard treatment for GCT is thorough curettage with adjuvant treatment such as phenol, liquid nitrogen, high-speed burr, or methylmethacrylate cement. This article presents the case of a 30-year-old male with GCT of the right distal femur, which demonstrated a complete necrosis of GCTB. Interestingly, the specimen also showed adipocytic lineage, and strong expression of apoptotic markers by [terminal deoxynucleotidyl-transferase dUTP nick-end labelling (TUNEL) and caspase-3] and peroxisome proliferator-activated receptor gamma (PPARγ). To the Authors' knowledge, this is the first reported case of complete necrosis of GCTB concurrent with adipocytic lineage and high expression of PPARγ. PPARγ is a master regulator of fat differentiation. PPARγ possesses antitumor activity through suppression of tumor proliferation and invasion and induction of differentiation and apoptosis. Although we could not conclude on the exact cause of complete necrosis and high expression of PPARγ in this case, we focused on the medical history, where this patient took zaltoprofen (240 mg/day) for four weeks before the biopsy to alleviate his pain. Zaltoprofen is a propionic-acid derivative non-steroidal anti-inflammatory drug, and it is reported to act as a direct ligand for PPARγ. We speculated that one of the possible mechanisms of PPARγ activation in this case was induction by zaltoprofen, at least in part. Although further analysis using cultured tumor cells with ligands specific to the receptor is necessary, PPARγ may be a novel therapeutic target in GCTB.

Entities:  

Keywords:  Giant cell tumor of bone; apoptosis; peroxisome proliferator-activated receptor gamma (PPARγ)

Mesh:

Substances:

Year:  2013        PMID: 23645771

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma.

Authors:  Akihiko Takeuchi; Norio Yamamoto; Toshiharu Shirai; Katsuhiro Hayashi; Shinji Miwa; Seiichi Munesue; Yasuhiko Yamamoto; Hiroyuki Tsuchiya
Journal:  BMC Cancer       Date:  2016-07-11       Impact factor: 4.430

2.  Anti-tumor effects of a nonsteroidal anti-inflammatory drug zaltoprofen on chondrosarcoma via activating peroxisome proliferator-activated receptor gamma and suppressing matrix metalloproteinase-2 expression.

Authors:  Takashi Higuchi; Akihiko Takeuchi; Seiichi Munesue; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Hiroyuki Inatani; Shingo Shimozaki; Takashi Kato; Yu Aoki; Kensaku Abe; Yuta Taniguchi; Hisaki Aiba; Hideki Murakami; Ai Harashima; Yasuhiko Yamamoto; Hiroyuki Tsuchiya
Journal:  Cancer Med       Date:  2018-03-23       Impact factor: 4.452

3.  Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.

Authors:  Akihiko Takeuchi; Akihiro Nomura; Norio Yamamoto; Katsuhiro Hayashi; Kentaro Igarashi; Susumu Tandai; Akira Kawai; Akihiko Matsumine; Shinji Miwa; Yoshihiro Nishida; Tomoki Nakamura; Ryu Terauchi; Manabu Hoshi; Toshiyuki Kunisada; Makoto Endo; Kenichi Yoshimura; Toshinori Murayama; Hiroyuki Tsuchiya
Journal:  BMC Musculoskelet Disord       Date:  2019-02-09       Impact factor: 2.362

4.  Evaluation of the expression pattern and diagnostic value of PPARγ in malignant and benign primary bone tumors.

Authors:  Amir Reza Eghtedari; Mohammad Amin Vaezi; Banafsheh Safizadeh; Ghasem Ghasempour; Pegah Babaheidarian; Vahid Salimi; Masoumeh Tavakoli-Yaraki
Journal:  BMC Musculoskelet Disord       Date:  2022-08-03       Impact factor: 2.562

5.  Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: The REALIZE study.

Authors:  Akihiko Takeuchi; Makoto Endo; Akira Kawai; Yoshihiro Nishida; Ryu Terauchi; Akihiko Matsumine; Hisaki Aiba; Tomoki Nakamura; Susumu Tandai; Toshifumi Ozaki; Manabu Hoshi; Daiki Kayano; Miho Okuda; Norio Yamamoto; Katsuhiro Hayashi; Shinji Miwa; Kentaro Igarashi; Kenichi Yoshimura; Akihiro Nomura; Toshinori Murayama; Hiroyuki Tsuchiya
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.